The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

abbisko.com

Stage

IPO | IPO

Total Raised

$263M

Date of IPO

10/13/2021

Market Cap

2.74B

About Abbisko Therapeutics

Abbisko Therapeutics (02256.HK) focuses on small molecule immunomodulators for cancers prevalent in Asia, using a combination of in-house R&D and outside CROs.

Abbisko Therapeutics Headquarter Location

Zhangjiang Hi-Tech Park 898 Harley Rd. Building 3

Shanghai, Shanghai, 100004,

China

+86 021-38122901

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Abbisko Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Abbisko Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Abbisko Therapeutics Patents

Abbisko Therapeutics has filed 8 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Transcription factors
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/1/2018

4/26/2022

Experimental cancer drugs, Tyrosine kinase receptors, Transcription factors, Monoclonal antibodies, Clusters of differentiation

Grant

Application Date

8/1/2018

Grant Date

4/26/2022

Title

Related Topics

Experimental cancer drugs, Tyrosine kinase receptors, Transcription factors, Monoclonal antibodies, Clusters of differentiation

Status

Grant

Latest Abbisko Therapeutics News

Abbisko Therapeutics Announces Worldwide Collaboration With Lilly To Discover And Develop Novel Molecules

Jan 21, 2022

Collaboration Combines Abbisko Therapeutics' Proprietary Drug Discovery Platform with Lilly's Disease and Discovery Expertise. Shanghai /PRNewswire/ - Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), today announced that it has entered into a worldwide collaboration and exclusive licensing agreement (the "Agreement") with Eli Lilly and Company ("Lilly") for the further discovery, development and potential commercialization of novel molecules against an undisclosed target for cardiometabolic diseases with critical unmet medical needs. Under the terms of the Agreement, Abbisko Therapeutics will be responsible for the further discovery and development of molecules that modulate a novel and challenging drug target using its proprietary R&D platform. Lilly will join the effort by providing prior discovery information associated with this target as well as certain additional disease knowledge and expertise. If Abbisko Therapeutics is successful in advancing the compounds to the agreed upon endpoints, Lilly will have the right to further develop and commercialize the opportunity. If Lilly elects not to advance the compounds, Abbisko Therapeutics will then have the right to further develop and commercialize. The Agreement will allow each party the opportunity to fully leverage both parties' existing compounds, platform and technologies related to the target globally to maximize patient treatment choice. "During the past five years, Abbisko Therapeutics has established a world-class discovery engine with a proprietary platform that has delivered ten drug candidates including four already in clinical trials," said Dr. Yao-Chang Xu, CEO of Abbisko Therapeutics. "We are excited to leverage this platform to collaborate with Lilly on this truly novel R&D collaboration to develop innovative medicines against a critical drug target. This collaboration could significantly expand our pipeline and strengthen our capabilities as we strive to bring novel therapies to patients and their families." Abbisko Therapeutics is eligible to receive up to US$258 million in potential payments based on the achievement of prespecified preclinical, clinical development and commercial milestones, as well as tiered royalties on sales resulting from the Agreement if Lilly is responsible for clinical development and commercialization. If Abbisko Therapeutics is responsible for clinical development and commercialization, then Lilly would receive development and commercialmilestone payments, as well as tiered royalties on sales resulting from the Agreement. (Note) Note: The payments to be paid or received by Abbisko Therapeutics are subject to achievement of relevant milestone events. There is no guarantee that such milestone events could be achieved. Source: Abbisko

Abbisko Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Abbisko Therapeutics Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.